Do four SGLT2 inhibitors lead to different cardiorenal benefits in type 2 diabetes, in chronic heart failure, and in chronic kidney disease?

Published:January 20, 2021DOI:
      Large randomized trials have confirmed the cardiorenal benefits from sodium-glucose transporter 2 (SGLT2) inhibitors for patients with type 2 diabetes (T2D), for patients with chronic heart failure and reduced ejection fraction (HFrEF), and for patients with chronic kidney disease (CKD). However, whether these cardiorenal benefits vary in different chronic diseases or vary with specific SGLT2 inhibitors remains unclear. Thus, we conducted this meta-analysis based on cardiovascular and renal outcome trials of SGLT2 inhibitors, and aimed at exploring the differences in the cardiorenal benefits from four SGLT2 inhibitors in three chronic diseases.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Heerspink H.
        • Stefánsson B.V.
        • Correa-Rotter R.
        • et al.
        Dapagliflozin in Patients with Chronic Kidney Disease.
        N Engl J Med. 2020;
        • Packer M.
        • Anker S.D.
        • Butler J.
        • et al.
        Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
        N Engl J Med. 2020;
        • Cannon C.P.
        • Pratley R.
        • Dagogo-Jack S.
        • et al.
        Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
        N Engl J Med. 2020;
        • McMurray J.
        • Solomon S.D.
        • Inzucchi S.E.
        • et al.
        Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
        N Engl J Med. 2019; 381: 1995-2008
        • Perkovic V.
        • Jardine M.J.
        • Neal B.
        • et al.
        Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
        N Engl J Med. 2019; 380: 2295-2306
        • Wiviott S.D.
        • Raz I.
        • Bonaca M.P.
        • et al.
        Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
        N Engl J Med. 2019; 380: 347-357
        • Neal B.
        • Perkovic V.
        • Mahaffey K.W.
        • et al.
        Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
        N Engl J Med. 2017; 377: 644-657
        • Zinman B.
        • Wanner C.
        • Lachin J.M.
        • et al.
        Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
        N Engl J Med. 2015; 373: 2117-2128
        • Zelniker T.A.
        • Wiviott S.D.
        • Raz I.
        • et al.
        SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
        Lancet. 2019; 393: 31-39
        • Zannad F.
        • Ferreira J.P.
        • Pocock S.J.
        • et al.
        SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
        Lancet. 2020;